[PRESS RELEASE] – EDMONTON, Alberta, April 15, 2025 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced the availability of medical cannabis concentrates to patients in the United Kingdom. This launch marks the company's meaningful step in offering its proprietary cultivar-specific inhalable cannabis extracts in the U.K. market. These products are available to patients in Canada and Australia, and this launch reinforces Aurora's commitment to expanding patient access to an even greater variety of high-quality, premium medical cannabis globally.
"As a company dedicated to patient care and ensuring we regularly listen to patient feedback, we recognized a real need for a convenient and discreet consumption option and are excited to introduce a new cannabis format at a promised level of quality," said Trisha Cassidy, managing director of Aurora U.K. and Ireland. "Our launch of inhalable cannabis cartridges are another step forward in our mission to provide physicians with a larger variety of high-quality medical cannabis that can meet the growing needs and wishes of patients here in the U.K. We look forward to receiving feedback from physicians and patients with this expanded offering."
The two novel cultivar-specific Aurora 1.2-gram resin cartridges have been developed from two highly sought-after proprietary cultivars: Sourdough (indica) and Electric Honeydew (sativa). The inhalation method of these cartridges offers an ideal solution for the fast and controlled delivery of medical cannabis.
[PRESS RELEASE] – EDMONTON, Alberta, April 15, 2025 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced the availability of medical cannabis concentrates to patients in the United Kingdom. This launch marks the company's meaningful step in offering its proprietary cultivar-specific inhalable cannabis extracts in the U.K. market. These products are available to patients in Canada and Australia, and this launch reinforces Aurora's commitment to expanding patient access to an even greater variety of high-quality, premium medical cannabis globally.
"As a company dedicated to patient care and ensuring we regularly listen to patient feedback, we recognized a real need for a convenient and discreet consumption option and are excited to introduce a new cannabis format at a promised level of quality," said Trisha Cassidy, managing director of Aurora U.K. and Ireland. "Our launch of inhalable cannabis cartridges are another step forward in our mission to provide physicians with a larger variety of high-quality medical cannabis that can meet the growing needs and wishes of patients here in the U.K. We look forward to receiving feedback from physicians and patients with this expanded offering."
The two novel cultivar-specific Aurora 1.2-gram resin cartridges have been developed from two highly sought-after proprietary cultivars: Sourdough (indica) and Electric Honeydew (sativa). The inhalation method of these cartridges offers an ideal solution for the fast and controlled delivery of medical cannabis.
Key benefits of cannabis inhalers include:
- Exceptional Flavor Profiles: Connected to popular flower products, these strain-specific cartridges use high-quality terpenes and pure extracts to deliver rich and authentic flavors.
- High Potency: Ensures a powerful, consistent, controllable experience with each dose.
- Safety and Quality: Manufactured in state-of-the-art facilities, adhering to strict TGA-GMP quality control and safety standards. These cartridges contain no additives, representing the pinnacle of cannabis purity.
- User-Friendly Design: Easy to use, making it a convenient, portable and discreet choice for patients.
Aurora's industry-leading portfolio of cannabis products is available nationwide for cannabis retailers to offer. Patients may contact their clinic for further information or consult their doctor.
